Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 10, 2003, Pages 465-469

  Morath, Christian ^a   Zeier, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Mycophenolate mofetil; Non immune cells; Proliferation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIMITOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRODRUG; STREPTOZOCIN;

BLOOD VESSEL INJURY; BONE MARROW SUPPRESSION; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBROBLAST; FOCAL GLOMERULOSCLEROSIS; GRAFT REJECTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MESANGIUM CELL; MINIMAL CHANGE GLOMERULONEPHRITIS; MITOSIS INHIBITION; NEPHROTOXICITY; NONHUMAN; PROTEINURIA; RENOVASCULAR HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES;

EID: 0141892569     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41465     Document Type: Review

References (39)

1. Allison AC, Eugui EM 2000 Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118
2. Aw MM, Samaroo B, Baker AJ, Verma A, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A 2001 Calcineurin inhibitor-related nephrotoxicity reversibility in pediatric liver transplant recipients. Transplantation 72: 746-749
3. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M 2000 Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58: 51-61
4. Badid C, Desmouliere A, Laville M 2001 Mycophenolate mofetil: implications for the treatment of glomerular disease. Nephrol Dial Transplant 16: 1752-1756
5. Baer PC, Gauer S, Hauser IA, Scherberich JE, Geiger H 2000 Effects of mycophenolic acid on human renal proximal and distal tubular bells in vitro. Nephrol Dial Transplant 15: 184-190
6. Briggs WA, Choi MJ, Scheel PJ, Jr. 1998 Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31: 213-217
7. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN 2000 Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162
8. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA 2002 Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61: 1098-1114
9. Dubus I, Vendrely B, Christophe I, Labouyrie JP, Delmas Y, Bonnet J, Combe C 2002 Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 62: 857-867
10. Fraser-Smith EB, Rosete JD, Schatzman RC 1995 Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J Pharmacol Exp Ther 275: 1204-1208
11. Fujihara CK, Malheiros DM, Zatz R, Noronha ID 1998 Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519
12. Fujihara CK, de Lourdes Noronha I, Malheiros Antunes GR, de Oliveira IB, Zatz R 2000 Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11: 283-290
13. Fujihara CK, Avancini Costa Malheiros DM, de Lourdes Noronha I, de Nucci G, Zatz R 2001 Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 37: 170-175
14. Gregory CR, Pratt RE, Huie P, Shorthouse R, Dzau VJ, Billingham ME, Morris RE 1993 Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25: 770-771
15. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE 1995 Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59: 655-661
16. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M 1999 Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14: 58-63
17. Heinz C, Hudde T, Heise K, Steuhl KP 2002 Antiproliferative effect of mycophenolate mofetil on cultured human tenon fibroblasts. Graefes Arch Clin Exp Ophthalmol 240: 408-414
18. Hueso M, Bover J, Seron D, Gil-Vernet S, Sabate I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyo JM 1998 Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 66: 1727-1731
19. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL 1997 Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 16: 484-492
20. Moon JI, Kim YS, Kim MS, Kim EH, Kim HJ, Kim SI, Park K 2000 Effect of cyclosporine, mycophenolic acid and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study. Transplant Proc 32: 2026-2027
21. Morgera S, Neumayer HH, Fritsche L, Kuchinke S, Lampe D, Ahnert V, Bauer S, Mai I, Budde K 1998 Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis. Int J Clin Pharmacol Ther 36: 159-163
22. Muller J, Deppisch R, Wiesel M, Waldherr R, Zeier M 2002 Apoptosis of fibroblasts in the healing wound of renal transplant recipients and in cell culture by mycophenolic acid (MPA). J Am Soc Nephrol 13:183A
23. Muller V, Hamar P, Szabo A, Knust E, Vogelsang M, Heemann U 1998 Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. Transplant Proc 30: 982
24. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ 1999 Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10: 1965-1971
25. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B 2000 Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-2409
26. Penny MJ, Boyd RA, Hall BM 1998 Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 9: 2272-2282
27. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ, Rodriguez-Iturbe B 2001 Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281: F38-47
28. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, Hayry P 1995 Mycophenolate mofetil (MMF), RS-61443 inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transplant Immunol 3: 342-351
29. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A 1999 Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542-1549
30. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ 2001 Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232
31. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E 1999 Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55: 945-955
32. Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW 2002 Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13: 536-543
33. Sommerer C, Hergesell O, Nahm AM, Schwenger V, Waldherr R, Andrassy K, Zeier M 2002 Cyclosporin A toxicity of the renal allograft - a late complication and potentially reversible. Nephron 92: 339-345
34. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, de Lourdes Noronha I, Zatz R 2003 Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216
35. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH 1998 Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407-1415
36. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC 2001 Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59: 1567-1573
37. Yang CW, Ahn HJ, Kim WY, Li C, Kim HW, Choi BS, Cha JH, Kim YS, Kim J, Bang BK 2002 Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 62: 20-30
38. Zeier M, Deppisch R, Dikow R, Schwenger V, Wiesel M 2002 Inhibition of fibroblast growth by mycophenolic acid is mediated by apoptosis. Am J Transplant 2: 321
39. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP 1998 Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9: 2055-2066